Help clear the way with

Bimzelx Navigate Logo

Help make the treatment journey smooth from the start for your patients. 

Rapid Access

Eligible, commercially insured patients who experience delay or denial in coverage can secure their first dose of BIMZELX through BIMZELX Navigate Bridge.* 

 

View Full Terms and Eligibility
BIMZELX Navigate® Bridge.

No more than $15

Eligible, commercially insured patients may pay just $15 per dose of BIMZELX for up to two years while their insurance coverage is pending.*
Commercially insured patients with approved coverage may be eligible to receive BIMZELX for as little as $5 per dose.† 

 

View Full Terms and Eligibility
BIMZELX Navigate® Savings.

1 Point of Contact

Our Nurse Navigators serve as your patient’s single point of contact for answering questions they may have, from insurance coverage to injection training to financial assistance and much more.‡

For eligible, commercially insured patients only. Eligible patients who have a delay or denial of coverage may pay $15 per dose of BIMZELX for up to two years or until the patient’s commercial insurance plan approves coverage, whichever comes first. Please see full eligibility and terms at www.bimzelx.com/patient-support/navigate-benefits.

Eligible, commercially insured patients with approved coverage may pay as little as $5 per dose. Please see full eligibility and terms at www.bimzelx.com/patient-support/navigate-benefits.

Nurse Navigators do not provide medical advice and will refer patients to their healthcare professional for treatment-related questions.

BIMZELX Navigate® helps make the treatment journey smooth
from the start for your patients.

Patient savings & support overview

 

Get more information on the BIMZELX Navigate program.

 

Download guide

 

 

BC corner

The Biologic Coordinator (BC) training portal provides helpful information such as detailed
instructions on how to use the BIMZELX autoinjector and prefilled syringe. 

 

Visit BC corner

 

For Specialty Pharmacy use: BIMZELX

Navigate can help patients pay as little as $5

 

We have two options for your eligible, commercially insured patients:

  • Pay as little as $5 once insurance coverage is approved
  • Pay just $15 per dose for up to 2 years while insurance coverage is pending

 
For eligible patients who may have difficulty paying for medication, we can help find resources to assist with cost. Visit UCB Savings to sign up patients for copay assistance, and visit the HCP BIMZELX Navigate portal for Specialty Pharmacy resources.

Discover UCB savings

Visit the HCP Navigate portal

INDICATION

BIMZELX is indicated for the treatment of adult patients with active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, active ankylosing spondylitis, and moderate-to-severe plaque psoriasis patients who are candidates for systemic therapy or phototherapy.

INDICATION

BIMZELX is indicated for the treatment of adults with moderate-to-severe hidradenitis suppurativa.

IMPORTANT SAFETY INFORMATION

Suicidal Ideation and Behavior

BIMZELX may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been definitively established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, instruct to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.

Infections

BIMZELX may increase the risk of infections, including serious infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.

Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.

Liver Biochemical Abnormalities

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.

Inflammatory Bowel Disease

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

Immunizations

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

MOST COMMON ADVERSE REACTIONS

Most common (≥ 1%) adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, other candida infections, and fatigue.

Most common (≥2%) adverse reactions in PsA, nr-axSpA, and AS include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. Other most common (≥2%) adverse reactions specific to each indication include: urinary tract infections (PsA); cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections (nr-axSpA); injection site pain, rash, and vulvovaginal mycotic infections (AS).

Most common (≥ 2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections.

Most common (≥ 2%) adverse reactions in non-radiographic axial spondyloarthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections.

Most common (≥ 2%) adverse reactions in ankylosing spondylitis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, injection site pain, rash, and vulvovaginal mycotic infection.